Gautam Borthakur

Professor

  • 10172 Citations
  • 52 h-Index
1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Gautam Borthakur is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 31 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Myelodysplastic Syndromes Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
decitabine Medicine & Life Sciences
Leukemia, Myeloid, Chronic Phase Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

3 Citations (Scopus)

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Jain, P., Kantarjian, H., Boddu, P. C., Nogueras-González, G. M., Verstovsek, S., Garcia-Manero, G., Borthakur, G., Sasaki, K., Kadia, T. M., Sam, P., Ahaneku, H., O’Brien, S., Estrov, Z., Ravandi, F., Jabbour, E. & Cortes, J. E., Mar 26 2019, In : Blood Advances. 3, 6, p. 851-861 11 p.

Research output: Contribution to journalArticle

Open Access
Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Incidence
Confidence Intervals
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myelodysplastic Syndromes
Clinical Trials
Blood Platelets
Therapeutics
Standard of Care

BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment

Piya, S., Mu, H., Bhattacharya, S., Lorenzi, P. L., Davis, R. E., McQueen, T., Ruvolo, V., Baran, N., Wang, Z., Qian, Y., Crews, C. M., Konopleva, M., Ishizawa, J., James You, M., Kantarjian, H. M., Andreeff, M. & Borthakur, G., May 1 2019, In : Journal of Clinical Investigation. 129, 5, p. 1878-1894 17 p.

Research output: Contribution to journalArticle

Open Access
Stem Cell Niche
Proteolysis
Down-Regulation
Acute Myeloid Leukemia
Stem Cells
9 Citations (Scopus)

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

Zhang, H., Savage, S., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., Carlos, A., Henson, R., Lin, C., Searles, R., Ho, H., Lam, Y. L., Sweat, R., Follit, C., Jain, V., Lind, E. & 10 others, Borthakur, G., Garcia-Manero, G., Ravandi, F., Kantarjian, H. M., Cortes, J., Collins, R., Buelow, D. R., Baker, S. D., Druker, B. J. & Tyner, J. W., Dec 1 2019, In : Nature communications. 10, 1, 244.

Research output: Contribution to journalArticle

Open Access
leukemias
mutations
Acute Myeloid Leukemia
Mutation
inhibitors
Open Access
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Safety
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Generic Drugs